Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346938 | 0.92 | MEN1 (0.48) | TSHRLMNAMEN1KMT2AHPGDS | |
| SCHEMBL1346720 | 0.90 | MAOB (0.51) | HPGDSALDH1A1PDCD1LG2CD274BCHE | |
| SCHEMBL1344679 | 0.87 | NPC1 (0.44) | TSHRLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1346193 | 0.87 | KDM4E (0.41) | TSHRLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1345200 | 0.86 | CD274 (0.38) | TSHRLMNAMEN1KMT2AHPGDS | |
| SCHEMBL1344906 | 0.85 | GPR52 (0.40) | TSHRLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1346483 | 0.85 | CD274 (0.47) | LMNAHPGDSSMN1; SMN2PDCD1LG2CD274 | |
| SCHEMBL1347594 | 0.85 | PDCD1LG2 (0.37) | TSHRLMNAMEN1KMT2AHPGDS | |
| SCHEMBL1346781 | 0.84 | TUBB4A (0.42) | TSHRLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1347012 | 0.83 | KDM1A (0.52) | LMNAMEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | claimed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | claimed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | claimed |
| JP-2007511564-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | claimed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | claimed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-8063039-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-7968592-B2 | 3-aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A., (IT) | 2010-02-25 | — | — | US | disclosed |
| EP-1685103-B1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARM SPA (IT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-14 | — | — | US | disclosed |
| CN-1882536-A | 3-aminopyrrolidone derivatives | NEWRON PHARM SPA (IT) | 2006-12-20 | — | — | CN | disclosed |
| EP-1685103-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005054190-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1533298-A1 | 3-aminopyrrolidone derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135410-A1 | 3-Aminopyrrolidone derivatives | TRPC3, TRPV3, CACNA1D | TSHR 3650/4885LMNA 3866/4885MEN1 2396/4885 |
| US-20100048665-A1 | 3-AMINOPYRROLIDONE DERIVATIVES | TRPC3, TRPV3, CACNA1D | TSHR 3650/4885LMNA 3866/4885MEN1 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.